Lofexidine for Opiate Withdrawal - 1

National Institute on Drug Abuse (NIDA)66 enrolled

Overview

The purpose of this study is to evaluate lofexidine for opiate withdrawal.

An 11 day inpatient placebo-controlled, double-blind study of 96 opiate dependent, treatment seeking individuals randomized to 2 medication groups: lofexidine and placebo to be conducted in inpatient units at 3 treatment sites.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Opioid-Related Disorders

Interventions

LofexidineDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: Male or female as least 18 yrs of age \& above with a current dependence on heroin, morphine or hydromorphone according to DSM4 criteria; subject ; voluntarily given consent and signed informed consent; females using appropriate birth control method. Exclusion Criteria: Additional criteria available during screening at the site

Locations (3)

UCLA Medical Center

Los Angeles, California, United States

Columbia University

New York, New York, United States

Philadelphia Veterans Medical Center

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

Opiate withdrawal symptoms

Potential Abuse Liability

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.